百濟神州(06160.HK)啟動在研TYK2抑制劑BGB-23339的首次人體臨牀試驗
格隆匯11月23日丨百濟神州(06160.HK)發佈公吿,百濟神州於2021年11月22日(美國東部時間)宣佈BGB-23339的1期臨牀試驗完成了首例患者給藥。BGB-23339是一款由百濟神州科學家自主研發的在研型強效酪氨酸激酶2(TYK2)變構抑制劑。
根據披露,TYK2是JAK激酶家族成員之一,在多種免疫介導的疾病(如銀屑病和炎症性腸道疾病)中作為細胞因數信號通路的關鍵調節因數發揮作用。BGB-23339是一款強效、高選擇性的在研TYK2抑制劑,靶向TYK2的調節性假激酶(JH2)結構域。
百濟神州全球研發負責人汪來博士表示:“BGB-23339是百濟神州自主研發的一款高度選擇性、強效TYK2變構抑制劑,在臨牀前研究中展現出了極具潛力的活性。過去我們在腫瘤學方面取得的成績有目共睹,在此基礎上,百濟神州正進一步擴展至包括炎症與免疫等在內的那些存在高度未被滿足臨牀需求的疾病領域,通過開發新的藥物模式和平台技術,為患者帶來創新、具備影響力的高品質治療藥物。”
BGB-23339的首項1期人體試驗(NCT05093270)旨在評價BGB-23339的安全性、耐受性、藥代動力學及初步活性。該試驗預計將在澳大利亞和╱或中國入組至多 115例健康受試者。
百濟神州在血液腫瘤及實體瘤方面建立了廣泛的產品組合,在此基礎上,公司還將運用其卓越的科學研究及臨牀開發能力,攻克存在高度未被滿足的醫療需求的炎症與免疫疾病領域。百濟神州自主研發的高選擇性全新一代BTK抑制劑—-百悦澤®(澤布替尼)目前正在開展一項2期臨牀試驗,用於活躍增殖性狼瘡腎炎的治療。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.